AMGN241129P312500
- 32.35
- 0.000.00%
Amgen Newsroom
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
Boeing, NVIDIA Corp. Share Gains Contribute To Dow's 261-Point Jump
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $360
Beigene's commercialized products for multiple indications are included in the new version of the national medical insurance drug list.
Beigene (06160) announced that its self-developed anti-PD-1 antibody drug, Baizean (Tiragolumab injection), and BTK inhibitor, Baiyueze (Zebutini capsule), have added three new indications and one indication has been included in the National Medical Insurance Catalog; Luye Pharma's co-introduced product, Baituowei (Goserelin injection microspheres), has added one indication included in the National Medical Insurance Catalog; Amgen's authorized introduced product, Kyprolis (Carfilzomib for injection), has successfully been renewed. The National Medical Insurance Catalog will be officially implemented starting January 1, 2025. This time the company's products Baizean and Baiyueze.
Should You Be Excited About Amgen Inc.'s (NASDAQ:AMGN) 56% Return On Equity?
Wednesday Ends With Index Decline | Wall Street Today
AMGN Stock Down Despite Strong Data From Obesity Drug Study
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Daily short sale tracking: GameStop's short volume increased by 1 million, with a short sale ratio of 12%
BMO Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
Truist Financial Maintains Amgen(AMGN.US) With Hold Rating
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $305 to $380
Today's Analyst Rating | Amgen Price Target Raised to $305 by Deutsche Bank, Applovin Price Target Raised to $400 by Jefferies
Amgen's Obesity Candidate MariTide Must Mitigate Tolerability Issues to Compete With Blockbuster Tirzepatide, Truist Says
Amgen's Stock Closes off Lows to Avoid Worst Day in 24 Years as Weight-loss-drug Data Underwhelms
Truist Financial Sticks to Their Hold Rating for Amgen (AMGN)
Trump Taps Jay Bhattacharya to Lead National Institutes of Health